Search - tctmd.com

Displaying 901 - 920 of 1806

Sort: Relevancy | Date

Presentation TCT 2016

Case #3: CTO PCI: Keep It Simple

Presenter: Afzalur Rahman, Kaisar Nasrullah Khan

October 30, 2016

Presentation TCT 2016

A Proximal LAD Chronic Total Occlusion. How Did I Treat It?

Presenter: Ricardo Lluberas, Jeffrey W. Moses, Jamil Abdalla Saad, Fernando Cura

October 30, 2016

Presentation TCT 2016

Case #2: Bifurcation PCI: Keep It Simple

Presenter: Afzalur Rahman, Alaide Chieffo

October 30, 2016

Presentation TCT 2016

Case 2: A Complex Left Main Bifurcation: How Did I Treat it?

Presenter: Ricardo Lluberas, Jeffrey W. Moses, Jamil Abdalla Saad, Mario Araya

October 30, 2016

Presentation TCT 2016

Comments and What I Might Have Done Differently

Presenter: Ricardo Lluberas, Jeffrey W. Moses, Jamil Abdalla Saad, Fausto Feres

October 30, 2016

Presentation TCT 2016

Case #1: Left Main PCI: Keep It Simple

Presenter: Afzalur Rahman

October 30, 2016

Presentation TCT 2016

Case 1: Primary PTCA With High Thrombotic Burden: How Did I Treat it?

Presenter: Ricardo Lluberas, Jeffrey W. Moses, Jamil Abdalla Saad, Gustavo S. Vignolo

October 30, 2016

Presentation TCT 2016

Welcome and Introductory Remarks

Presenter: Afzalur Rahman

October 30, 2016

Presentation TCT 2016

Low-Risk Studies: Design and Updates II - The PARTNER 3 Low-Risk Trial

Presenter: Patrick T. O'Gara, Alec S. Vahanian, Michael J. Mack

October 30, 2016

Presentation TCT 2016

Intermediate-Risk Studies I: Synthesis of the PARTNER 2A and the Sapien 3 Intermediate-Risk Trials

Presenter: Patrick T. O'Gara, Alec S. Vahanian, Susheel K. Kodali

October 30, 2016

Presentation TCT 2016

Physician and Management Partnerships: Benefits and Challenges

Presenter: Robert J. Applegate, Charles E. Chambers, Megan Berlinger

October 29, 2016

News Industry News

Academic Research Organization HCRI Changes Name to The Baim Institute for Clinical Research

October 27, 2016

News Industry News

Corindus Vascular Robotics Receives FDA Clearance for Next Generation Robotic System

October 27, 2016

News Opinion Editor's Corner TCT 2016

TCT 2016: Inspiration and Perspiration Greet Left Main Stenting, Hoop Dreams, Valve Innovation, and Election Fever

Shelley Wood

October 24, 2016

News Daily News

Oral Anticoagulation Use Common in PCI Patients, With Triple Therapy the Norm at Discharge

Todd Neale

October 18, 2016

News Daily News

TAVR 3 年后瓣膜性能持稳，大多数死亡非心脏相关：FRANCE 2 登记表

Caitlin E. Cox

October 04, 2016

News Daily News

Registro FRANCE 2: 3 Años Después de una TAVR, el Rendimiento de la Válvula se Mantiene y casi Toda la Mortalidad es No Cardíaca

Caitlin E. Cox

October 04, 2016

News Daily News

At 3 Years Post-TAVR, Valve Performance Holds Steady and Most Mortality Is Noncardiac: FRANCE 2 Registry

Caitlin E. Cox

October 04, 2016

News Industry News

SentreHEART Announces Closing of $35M Funding Round for aMAZE Trial

October 03, 2016

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for September 2016

Shelley Wood

September 30, 2016

Advertisement

Case #3: CTO PCI: Keep It Simple

A Proximal LAD Chronic Total Occlusion. How Did I Treat It?

Case #2: Bifurcation PCI: Keep It Simple

Case 2: A Complex Left Main Bifurcation: How Did I Treat it?

Comments and What I Might Have Done Differently

Case #1: Left Main PCI: Keep It Simple

Case 1: Primary PTCA With High Thrombotic Burden: How Did I Treat it?

Welcome and Introductory Remarks

Low-Risk Studies: Design and Updates II - The PARTNER 3 Low-Risk Trial

Intermediate-Risk Studies I: Synthesis of the PARTNER 2A and the Sapien 3 Intermediate-Risk Trials

Physician and Management Partnerships: Benefits and Challenges

Academic Research Organization HCRI Changes Name to The Baim Institute for Clinical Research

Corindus Vascular Robotics Receives FDA Clearance for Next Generation Robotic System

TCT 2016: Inspiration and Perspiration Greet Left Main Stenting, Hoop Dreams, Valve Innovation, and Election Fever

Oral Anticoagulation Use Common in PCI Patients, With Triple Therapy the Norm at Discharge

TAVR 3 年后瓣膜性能持稳，大多数死亡非心脏相关：FRANCE 2 登记表

Registro FRANCE 2: 3 Años Después de una TAVR, el Rendimiento de la Válvula se Mantiene y casi Toda la Mortalidad es No Cardíaca

At 3 Years Post-TAVR, Valve Performance Holds Steady and Most Mortality Is Noncardiac: FRANCE 2 Registry

SentreHEART Announces Closing of $35M Funding Round for aMAZE Trial

TCTMD’s Top 10 Most Popular Stories for September 2016

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content